Publications Archive - European Myeloma Network

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Main author: Dimopoulos

DOI: 10.1016/S1470-2045(21)00128-5

Publication date: June 2021

Connected Trials: EMN14

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde

Main author: Musto

DOI: 10.3324/haematol.2021.278519

Publication date: May 2021

Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network

Main author: Gramatzki

Publication date: April 2021

Connected Trials: EMN09

Minimal Residual Disease Assessment by Multiparameter Flow Cytometry in Transplant-Eligible Myeloma in the EMN02/HOVON 95 MM Trial

Main author: Oliva

Publication date: April 2021

Connected Trials: EMN02

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Main author: Ludwig

DOI: 10.1038/s41375-020-01016-0

Publication date: August 2020

Autologous Haematopoietic Stem-Cell Transplantation Versus Bortezomib-Melphalan-Prednisone, With or Without Bortezomib-Lenalidomide-Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (EMN02/HO95): A Multicentre, Randomised, Open-Label, Phase 3 Study

Main author: Cavo

DOI: 10.1016/S2352-3026(20)30099-5

Publication date: June 2020

Connected Trials: EMN02

Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network.

Main author: Cook

DOI: 10.1038/s41375-020-0918-6

Publication date: June 2020

Management of Patients With Multiple Myeloma in the Era of COVID-19 Pandemic: A Consensus Paper From the European Myeloma Network (EMN)

Main author: Terpos

DOI: 10.1038/s41375-020-0876-z

Publication date: May 2020

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Main author: Terpos

DOI: https://doi.org/10.1038/s41375-020-0876-z

Publication date: May 2020

Time From First Symptom Onset to the Final Diagnosis of Multiple Myeloma (MM) – Possible Risks and Future Solutions: Retrospective and Prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network’ (EMN) Analysis

Main author: Graziani

DOI: 10.1080/10428194.2019.1695051

Publication date: April 2020

Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma: A Consensus Statement From The European Myeloma Network

Main author: Moreau

DOI: 10.3324/haematol.2019.224204

Publication date: December 2019

Lenalidomide Maintenance With or Without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis

Main author: Bonello

DOI: 10.3390/cancers11111735

Publication date: November 2019

Connected Trials: EMN01

Minimal Residual Disease by Flow Cytometry and Allelic-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction in Patients With Myeloma Receiving Lenalidomide Maintenance: A Pooled Analysis

Main author: Gambella

DOI: 10.1002/cncr.31854

Publication date: March 2019

Connected Trials: EMN02

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A Consensus Paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Main author: Bringhen

DOI: 10.1111/joim.12882

Publication date: February 2019

Insights on Multiple Myeloma Treatment Strategies

Main author: Mateos

DOI: 10.1097/HS9.0000000000000163

Publication date: December 2018

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when

Main author: Caers

DOI: 10.3324/haematol.2018.189159

Publication date: November 2018

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Main author: Gay

DOI: 10.1001/jamaoncol.2018.2961

Publication date: October 2018

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

Main author: Gavriatopoulou

DOI: 10.1038/s41375-018-0209-7

Publication date: September 2018

Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA)

Main author: Bringhen

DOI: 10.3324/haematol.2018.191288

Publication date: September 2018

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Main author: Gay

DOI: 10.3324/haematol.2017.174573

Publication date: February 2018

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

Main author: Bringhen

DOI: 10.1038/s41375-018-0024-1

Publication date: January 2018

Connected Trials: EMN07

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Main author: Larocca

DOI: 10.1038/s41375-018-0142-9

Publication date: January 2018

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Main author: Ludwig

DOI: 10.1038/s41375-018-0040-1

Publication date: January 2018

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network

Main author: Ludwig

DOI: 10.1038/leu.2017.353

Publication date: January 2017

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.

Main author: Magarotto

DOI: 10.1182/blood-2015-08-662627

Publication date: January 2016

Connected Trials: EMN01